Phase II Trial: Undifferentiated Versus Differentiated Autologous Mesenchymal Stem Cells Transplantation in Egyptian Patients with HCV Induced Liver Cirrhosis

El-Ansary, Mervat; Abdelaziz, Iman; Mogawer, Sherif; Abdel-Hamid, Samah M.; Hammam, Olfat; Teaema, Salwa; Wahdan, Marwa

doi:10.1007/s12015-011-9322-y

Cited by 155 publications

(131 citation statements)

References 31 publications

Supporting

Mentioning

123

Contrasting

Order By: Relevance

“…These results agree with different studies suggested a supportive role of undifferentiated WJ-MSCs in rescuing injured liver functions [24]. In addition, WJ-MSCs have properties of anti-inflammatory and antifibrosis by endogenous secreted factors such as metalloproteinase [25].…”

Section: Discussionsupporting

confidence: 92%

Camel’s wharton jelly mesenchymal stem cell is a novel tool for regeneration of induced diabetes mellitus

Miniawy¹,

Ahmed²,

Ibrahem³

et al. 2017

J Transl Sci

View full text Add to dashboard Cite

Wharton's jelly derived mesenchymal stem cell (WJ-MSC) possesses therapeutic properties. WJ-MSC was nontumorigenic, acquired high rate of proliferation and their immune privileged status make them ideal for both autologous and allogeneic use in regenerative medicine applications. This study examined the possible therapeutic potentials of camel WJ-MSC in regeneration of damaged pancreatic diabetic tissues in rats. Streptozotocin (STZ) induced diabetic rats showed pancreatic tissues degeneration in parallel with suppressed expressions of the insulin, smad-2, PDX-1 and SIRT-1. The infusion of WJ-MSC markedly alleviated the altered induced diabetes by significant increase in quantitative genes expression and significantly enhanced histopathological cellular integrity of islets of Langerhans and pancreatic acini compared to STZ group. The infusion of WJ-MSC enhanced the liver and kidneys functions supported by decrease of ALT, AST and urea levels than diabetic group. These findings shows for the first time the novel valuable therapeutic role of camel WJ-MSC on pancreatic tissue regeneration with function retrieval and reduced the side effects of STZ on the liver and kidneys.

show abstract

Section: Discussionsupporting

confidence: 92%

Camel’s wharton jelly mesenchymal stem cell is a novel tool for regeneration of induced diabetes mellitus

Miniawy¹,

Ahmed²,

Ibrahem³

et al. 2017

J Transl Sci

View full text Add to dashboard Cite

show abstract

“…In the field of liver cirrhosis, as shown in Table 1, many autologous [70][71][72][73][74][75][76][77][78][79][80][81][82][83] and four allogeneic [59][60][61][62] MSC therapies involving a variety of tissue origins and administration routes have been reported. Although details regarding the mechanisms of therapeutic effects in humans remain unclear, most studies have reported favorable effects with improvement in MELD scores, Child-Pugh scores, and some serum markers such as albumin and bilirubin.…”

Section: Mscsmentioning

confidence: 99%

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Terai

Tsuchiya

2016

J Gastroenterol

View full text Add to dashboard Cite

The treatment of liver cirrhosis is currently being standardized and developed specifically to reduce activation of hepatic stellate cells (HSCs), inhibit fibrosis, increase degradation of matrix components, and reduce activated myofibroblasts. Cell therapy can be applied in the treatment of liver cirrhosis; however, the characteristic features of this therapy differ from those of other treatments because of the involvement of a living body origin and production of multiple cytokines, chemokines, matrix metalloproteinases (MMPs), and growth factors. Thus, cell therapies can potentially have multiple effects on the damaged liver, including alleviating liver cirrhosis and stimulating liver regeneration with affecting the host cells. Cell therapies initially involved autologous bone marrow cell infusion, and have recently developed to include the use of specific cells such as mesenchymal stem cells and macrophages. The associated molecular mechanisms, routes of administration, possibility of allogeneic cell therapy, and host conditions appropriate for cell therapies are now being extensively analyzed. In this review, we summarize the status and future prospects of cell therapy for liver cirrhosis.

show abstract

“…A subsequent study in 2012 assessed the potential effects of hepatocyte-like cells differentiated from BMMSCs prior to infusion as compared to undifferentiated BM-MSCs in 25 liver cirrhosis patients [55]. While this study showed that the intravenous infusion of 1 × 10 6 cells per kg body weight is safe and improves liver function, the clinical outcomes between both treatment groups did not vary.…”

Section: Allogeneic Stem Cells In Liver Cirrhosis Therapymentioning

confidence: 93%

Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives

Subbanna¹,

Radha²,

Choy³

et al. 2017

Int J Stem Cell Res Ther

View full text Add to dashboard Cite

Phase II Trial: Undifferentiated Versus Differentiated Autologous Mesenchymal Stem Cells Transplantation in Egyptian Patients with HCV Induced Liver Cirrhosis

Abstract: Bone marrow MSCs transplantation either undifferentiated or differentiated can be used as a potential treatment for liver cirrhosis.

Cited by 155 publications

References 31 publications

Camel’s wharton jelly mesenchymal stem cell is a novel tool for regeneration of induced diabetes mellitus

Camel’s wharton jelly mesenchymal stem cell is a novel tool for regeneration of induced diabetes mellitus

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives

Contact Info

Product

Resources

About